Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEMPO antidepressant discontinuation trial
2021-006108-34Phase 4Active
- Sponsor
- Amsterdam University Medical Center
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of paroxetine and venlafaxine in major depressive disorder (MDD) (3 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Rate of failure to successfully discontinue antidepressant. Started Aug 2022; status: active.
02
Drugs
paroxetinevenlafaxine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2021-006108-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006108-34.